This study is currently not recruiting participants.

GS-US-339-1560; A Phase 1b Open-Label Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

This study will evaluate the safety, efficacy, tolerability, and pharmacokinetics of entospletinib (GS-9973) in combination with vincristine (VCR), and dexamethasone in adults with previously treated relapsed or refractory B-cell lineage acute lymphoid leukemia (ALL).

Description

The purpose of this study is to evaluate safety of entosplentinib (GS-9973) in combination with vincristine and dexamethasone in adult subjects with previously treated relapsed or refractory B-cell lineage Acute Lymphoid Leukemia (ALL).

Details
Condition acute lymphoid leukemia
Age 18years - 100years
Clinical Study IdentifierTX5478
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.